Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 22, 2016

Vinorelbine With Pertuzumab and Trastuzumab as First Line in HER2+ Metastatic Breast Cancer

Breast Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research
Safety and Efficacy of Vinorelbine in Combination With Pertuzumab and Trastuzumab for First-Line Treatment of Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer: VELVET Cohort 1 Final Results
Breast Cancer Res 2016 Dec 13;[EPub Ahead of Print], EA Perez, JM López-Vega, T Petit, C Zamagni, V Easton, J Kamber, E Restuccia, M Andersson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading